These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32885397)

  • 21. Center for Drug Evaluation and Research Perspective on Quality in Clinical Trials.
    Shapley S; O'Shaughnessy J; Woodcock J
    Ther Innov Regul Sci; 2017 Jul; 51(4):416-418. PubMed ID: 30227045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A constructive critique of the
    Scharfstein DO
    Clin Trials; 2019 Aug; 16(4):375-380. PubMed ID: 31184495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical trials and the new good clinical practice guideline in Japan. An economic perspective.
    Ono S; Kodama Y
    Pharmacoeconomics; 2000 Aug; 18(2):125-41. PubMed ID: 11067647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimands in hematologic oncology trials.
    Sun S; Weber HJ; Butler E; Rufibach K; Roychoudhury S
    Pharm Stat; 2021 Jul; 20(4):793-805. PubMed ID: 33686762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?
    Lawrance R; Degtyarev E; Griffiths P; Trask P; Lau H; D'Alessio D; Griebsch I; Wallenstein G; Cocks K; Rufibach K
    J Patient Rep Outcomes; 2020 Aug; 4(1):68. PubMed ID: 32833083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimands and Complex Innovative Designs.
    Collignon O; Schiel A; Burman CF; Rufibach K; Posch M; Bretz F
    Clin Pharmacol Ther; 2022 Dec; 112(6):1183-1190. PubMed ID: 35253205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Practices in Choosing Estimands and Sensitivity Analyses in Clinical Trials: Results of the ICH E9 Survey.
    Fletcher C; Tsuchiya S; Mehrotra DV
    Ther Innov Regul Sci; 2017 Jan; 51(1):69-76. PubMed ID: 30236003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding estimands.
    Gogtay NJ; Ranganathan P; Aggarwal R
    Perspect Clin Res; 2021; 12(2):106-112. PubMed ID: 34012908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials.
    Jin M; Liu G
    Contemp Clin Trials; 2020 Sep; 96():106093. PubMed ID: 32777382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shared Learnings on the New EMA First-in-Human and Early Clinical Trial Guideline: Proceedings From a DIAlogue Session at DIA Europe 2018.
    van der Laan JW; Benson CT; Janssens W; Bos J; Stahl E; Brady JT; Wändel-Liminga U; Corriol-Rohou S; Forster R; Hartmann A; Pertel PE; Robertson SM; Silva-Lima B; Malik RE; Chibout SD
    Ther Innov Regul Sci; 2020 Mar; 54(2):462-467. PubMed ID: 32072587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementing Benefit-Risk Assessment for the Periodic Benefit-Risk Evaluation Report.
    Warner MR; Wolka AM; Noel RA
    Ther Innov Regul Sci; 2016 May; 50(3):342-346. PubMed ID: 30227065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group.
    Stat Med; 1999 Aug; 18(15):1905-42. PubMed ID: 10532877
    [No Abstract]   [Full Text] [Related]  

  • 34. Regional Differences During the ICH Regulatory Consultation Process Between the EU, US, and Japan.
    Torqui A; Macau AM
    Ther Innov Regul Sci; 2018 Jul; 52(4):438-441. PubMed ID: 29714552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Good Clinical Practice guideline and its interpretation - perceptions of clinical trial teams in sub-Saharan Africa.
    Vischer N; Pfeiffer C; Joller A; Klingmann I; Ka A; Kpormegbe SK; Burri C
    Trop Med Int Health; 2016 Aug; 21(8):1040-1048. PubMed ID: 27260671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Good intentions and ICH-GCP: Trial conduct training needs to go beyond the ICH-GCP document and include the intention-to-treat principle.
    Browne LH; Graham PH
    Clin Trials; 2014 Dec; 11(6):629-34. PubMed ID: 25023199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Seeking harmony: estimands and sensitivity analyses for confirmatory clinical trials.
    Mehrotra DV; Hemmings RJ; Russek-Cohen E;
    Clin Trials; 2016 Aug; 13(4):456-8. PubMed ID: 26908545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk based monitoring (RBM) tools for clinical trials: A systematic review.
    Hurley C; Shiely F; Power J; Clarke M; Eustace JA; Flanagan E; Kearney PM
    Contemp Clin Trials; 2016 Nov; 51():15-27. PubMed ID: 27641969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
    Teede HJ; Misso ML; Costello MF; Dokras A; Laven J; Moran L; Piltonen T; Norman RJ;
    Fertil Steril; 2018 Aug; 110(3):364-379. PubMed ID: 30033227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
    Teede HJ; Misso ML; Costello MF; Dokras A; Laven J; Moran L; Piltonen T; Norman RJ;
    Hum Reprod; 2018 Sep; 33(9):1602-1618. PubMed ID: 30052961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.